Acadian Asset Management LLC Kiniksa Pharmaceuticals, Ltd. Transaction History

Acadian Asset Management LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$17.63 - $21.74 $1.82 Million - $2.24 Million	103,120 Added 167.82%	164,568 $3.24 Million
Q4 2023 Feb 13, 2024	SELL	$14.37 - $19.07 $2.37 Million - $3.14 Million	-164,733 Reduced 72.83%	61,448 $1.08 Million
Q3 2023 Nov 13, 2023	BUY	$13.62 - $20.2 $2.78 Million - $4.12 Million	203,933 Added 916.64%	226,181 $3.92 Million
Q2 2023 Aug 07, 2023	BUY	$10.44 - $16.48 $53,129 - $83,866	5,089 Added 29.66%	22,248 $310,000
Q1 2023 May 11, 2023	BUY	$10.7 - $15.79 $44,351 - $65,449	4,145 Added 31.85%	17,159 $183,000
Q4 2022 Feb 14, 2023	BUY	$11.42 - $17.05 $148,619 - $221,888	13,014 New	13,014 $193,000
Q3 2020 Nov 09, 2020	SELL	$15.21 - $25.53 $213,259 - $357,956	-14,021 Closed	0 $0
Q2 2020 Aug 12, 2020	BUY	$15.08 - $26.0 $125,556 - $216,476	8,326 Added 146.2%	14,021 $357,000
Q1 2020 May 11, 2020	BUY	$11.0 - $19.76 $62,645 - $112,533	5,695 New	5,695 $88,000

1.95M

Ticker KNSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,470,400
Market Cap $687M
Description
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatm...

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Acadian Asset Management LLC with notifications on news.